Viewing Study NCT06189820



Ignite Creation Date: 2024-05-06 @ 7:55 PM
Last Modification Date: 2024-10-26 @ 3:17 PM
Study NCT ID: NCT06189820
Status: RECRUITING
Last Update Posted: 2024-01-05
First Post: 2023-11-22

Brief Title: Role of the Fibroblast Activation Protein FAP as Biomarker of Fibrotic Lung Diseases
Sponsor: Erasme University Hospital
Organization: Erasme University Hospital

Study Overview

Official Title: Role of the Fibroblast Activation Protein FAP as Biomarker of Fibrotic Lung Diseases
Status: RECRUITING
Status Verified Date: 2023-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: FAPIPET
Brief Summary: To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PETCT
Detailed Description: To evaluate the use of the fibroblast activation protein FAP as a biomarker of fibrotic lung disease idiopathic pulmonary fibrosis IPF and non-IPF ILDs The study will include both analysis of FAP expression in samples stored in the biobank of the department of Pneumology BAL blood induced sputum and EBC cohort A and lung FAPI uptake on PETCT scans performed at the department of Nuclear Medicine

before and after the initiation of an antifibrotic therapy IPF or PPF cohort B
before and after the initiation of corticosteroid therapy in case of an acute exacerbation of ILD cohort C
before and after the initiation of an immunosuppressive drug in the context of non-IPF pulmonary fibrosis cohort D
before lung transplantation surgery or biopsy to correlate with FAP expression determined by immunohistochemical analysis IHC cohort E

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None